TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04344821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curves Calcium
Description: Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curves Calcium
Description: Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curves Calcium
Description: Dietary Supplement: Curves Calcium~Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium \[as calcium citrate malate and calcium citrate\], 400 IU of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dextrose Placebo
Study: NCT02199782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Welsh language Cognitive Assessment
Description: This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Welsh language Cognitive Assessment
Description: This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
Study: NCT02211300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The OptiScanner
Description: treatment of blood glucose per standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YSI 2300 STAT Plus™
Study: NCT00081588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC114
Description: 600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
Study: NCT02185352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEEP regimen
Description: Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
Study: NCT04499157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMOPTIC
Description: Patients will receive their usual treatment of glaucoma adding 1 tablet of MEMOPTIC per day during 2 years of following

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual treatment of glaucoma
Description: Patients will receive only their usual treatment of glaucoma.
Study: NCT03891212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placed in prone position for at least 16 consecutive hours a day.
Description: Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
Study: NCT03609801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTV
Description: Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Duluth Model
Description: The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
Study: NCT04155931

Intervention type: OTHER
Intervention: body temperature measurement
Description: Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
Study: NCT01673334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration (FNA) and Core biopsy (FNB)
Study: NCT04258020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: Bilevel Positive Airway Pressure (BiPAP) oxygen administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Heated High Flow Nasal Cannula oxygen administration
Study: NCT03239041

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social navigation team
Description: Social navigation team
Study: NCT03760549

Intervention type: DRUG
Intervention: Subjects were administered NasoVAX high dose
Description: NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
Study: NCT01820130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St Jude Medical EON mini rechargeable system
Description: implantation of Eon Mini Neurostimulation System (IPG Model 3788)
Study: NCT00902616

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: 3gm TDS for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lactose powder
Description: 3gm TDS for 3 months
Study: NCT02284737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PADN
Description: Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham PADN
Description: The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sildenafil
Description: Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
Study: NCT02664428

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PreBIOil
Description: A daily dose of about 90 gram will be given for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: A daily dose of about 90 gram will be given for 8 weeks
Study: NCT00779246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal swabs for MRSA culture
Description: Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal swabs for MRSA culture
Description: Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contact isolation
Description: All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
Study: NCT04715594

Intervention type: DEVICE
Intervention: 1st-generation drug-eluting stent
Description: Implantation of 1st-generation drug-eluting stent

Intervention type: DEVICE
Intervention: 2nd-generation drug-eluting stents
Description: Implantation of 2nd-generation drug-eluting stent
Study: NCT01795001

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT01946061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin
Description: Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
Study: NCT01842828

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care plus electronic cigarettes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care plus electronic cigarettes

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard care
Study: NCT04193202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Administered twice daily as an oral tablet of 45 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice daily as a placebo oral tablet matching gefapixant
Study: NCT03095417

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise Intervention
Description: In home exercise intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise Intervention
Description: In home exercise intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training Intervention
Description: Online cognitive training modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training Intervention
Description: Online cognitive training modules.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching Control
Description: In home stretching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Control
Description: In home stretching.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Control
Description: Online control puzzles and games.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Control
Description: Online control puzzles and games.
Study: NCT04071873

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point-of-care HIV testing
Description: Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing education
Description: Participants will be provided with education on community based HIV resources.
Study: NCT02667912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal renal denervation
Description: Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches of the renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional renal denervation
Description: Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of the renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
Study: NCT01751568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
Study: NCT01879709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Training
Description: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
Study: NCT03451227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Group
Description: Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
Study: NCT01751568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
Study: NCT01063010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously for 90 minutes (+ 15 minutes)
Study: NCT02755493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Study: NCT00279149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visio conference system connected to the Tele-stroke network
Description: Visio conference system connected to the Tele-stroke network
Study: NCT00650949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT997
Description: Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
Study: NCT01144104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Service Announcement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Multi-Media Computer Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Video
Study: NCT04950335

Intervention type: PROCEDURE
Intervention: AOPT
Description: The Osteochondral Autograft Transplant System (Arthrex) was used to create donor plugs. Osteoperiosteal grafts were harvested from the ipsilateral anterior superior iliac spine.

Intervention type: PROCEDURE
Intervention: AOCT
Description: Osteochondral grafts were harvested from the non-weight-bearing zone of the ipsilateral anterolateral distal femur.
Study: NCT03652103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Erector Spinae Plane Block Catheterisation
Description: After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Perineural Injection
Study: NCT02782481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00781326

Intervention type: DRUG
Group type: OTHER
Intervention: Nimodipine
Description: Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
Study: NCT02083770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Clinical Trials Education Program
Description: Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cancer Clinical Trials Education Program
Description: Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
Study: NCT00781326

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo will be given in doses matching those of nimodipine.
Study: NCT03028376

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
Study: NCT02067013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Ranibizumab
Description: Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
Study: NCT02416323

Intervention type: OTHER
Group type: OTHER
Intervention: AIM HI Training
Study: NCT01747980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-112
Description: Single dose level, four doses per cohort
Study: NCT03717337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single visit pulp regeneration
Description: Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two visit pulp regeneration
Description: first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
Study: NCT02424916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melanoma antigens-specific CD8+ T lymphocytes
Description: The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
Study: NCT03400397

Intervention type: OTHER
Intervention: Cool Kids programme
Description: A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
Study: NCT02717091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + nab-paclitaxel
Study: NCT04641468

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DCB
Description: OCT technical guidance: if B-type or C-type dissection can be seen, Oct should be used for further evaluation, and des treatment should be conducted if necessary
Study: NCT04493099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT02285452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zingiberis Rhizoma plv.
Study: NCT02658851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Plasma
Description: Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
Study: NCT01714024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Trabecular Metal Test Cylinder
Description: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Trabecular Metal Test Cylinder
Description: For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
Study: NCT02285452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinapis nigrea semen